MA-PATHAI
21.5.2024 09:01:26 CEST | Business Wire | Press release
PathAI, a global leader in AI-powered pathology, today announced a new Early Access Program (EAP) to drive adoption of its AISightTM Image Management System (IMS) in Mainland Europe.1 Earlier in 2023, PathAI announced a similar program for laboratories in the United States, which attracted over 50 laboratories with many exploring long-term use of PathAI’s AISight Image Management System and broad menu of AI Products.
As part of the EAP, AP Laboratories in Europe can trial AISight, a modern and cloud-based digital pathology solution compliant with GDPR, as well as conduct and publish real-world validation studies of PathAI’s AI Products such as ArtifactDetect, TumorDetect, AIM-TumorCellularity, AIM-PD-L1, and AIM-HER2.2
“We are thrilled to commence a more dedicated focus to bring AISight Image Management System to labs in Europe. We have continued to make improvements on the platform with input from our first set of commercial customers in the U.S. We are excited to partner with European labs in democratizing access to digital pathology, enhancing pathologist experience, and ultimately improving patient outcomes,” said Nick Brown, Chief Growth Officer at PathAI.
AISight is a cloud-based platform that enables efficient end-to-end digital pathology workflows. AISight provides best-in-class caseload balancing and assignment, caselist prioritization, image ingestion, image viewing, collaboration tools, and image and case management. Via AISight Link, AISight can also be integrated bidirectionally with laboratory information systems for streamlined workflows. Anatomic pathology laboratories of all sizes and specialties – including health systems, university hospitals, and reference laboratories – may utilize AISight.
“PathAI has been an excellent thought partner for helping our institution think through what it means to create a modern, next-generation digital pathology workflow that spans versatile use cases like research, clinical trials, and diagnostics,” said Prof. Dr. Jan Budczies, Head of Medical Bioinformatics at the University of Heidelberg. “We are excited to partner with PathAI on this Early Access Program and look forward to taking advantage of their growing portfolio of features and algorithms on AISight, starting with our Molecular Pathology Department where we are especially interested in understanding the feasibility of estimating tumor cell content and characterizing immune cell infiltrates more precisely by leveraging digital pathology and artificial intelligence.”
AISight enables pathologists with seamless access to a broad array of algorithms to drive workflow optimization, standardized biomarker quantitation, and next-generation case prioritization including ArtifactDetect, TumorDetect, AIM-TumorCellularity, AIM-PD-L1 (NSCLC, HNSCC, Melanoma, Urothelial), and AIM-HER2 Breast Cancer and will also host third-party algorithms on request.
“We have trialed AISight at our department for several months now. At our Molecular Pathology Unit we are especially interested in understanding the feasibility of estimating tumor cell content through image analysis. PathAI’s AIM-TumorCellularity can be a tool that will change time to treatment for patients in need of molecular testing,” said Prof. Dr. Holger Moch, Director of Pathology at the University of Zurich and PathAI Advisor. “PathAI has been responsive to our unique needs and a valuable thought partner in helping us think through how to pick the most modern and innovative digital pathology solution on the market. We are excited about our partnership with PathAI and look forward to taking advantage of their growing portfolio of algorithms and feature improvements on AISight.”
“We have been leveraging the AIM-PD-L1 NSCLC and AIM-TumorCellularity NSCLC Algorithms over the past few months at our institution as part of a large research cohort,” said Dr. Jose Palacios, Director of Pathology at Ramon y Cajal Hospital in Madrid, Spain. “Given the success we’ve seen at our own institution, there has been increasing demand from across Spain to leverage these algorithms and we are working with more than 10+ hospitals across Spain to implement these tools.”
PathAI expects IVDR Certification of AISight Dx for primary diagnosis by Q3 2024. Early Access Program Participants will be the first to receive access to this platform. To learn more about AISight, visit our website. PathAI’s team will also be at upcoming conferences including the European Congress of Digital Pathology in Vilnius, Lithuania (June 5-8), European Congress of Pathology in Florence, Italy (September 7-11), and the DP/AI Congress in London, United Kingdom (December 7-8).
Footnotes
1 AISight™ is for research use only. Not for use in diagnostic procedures.
2 ArtifactDetect™, TumorDetect™, AIM-TumorCellularity™, AIM-PD-L1™ and AIM-HER2™ are research use only. Not for use in diagnostic procedures.
About PathAI
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases.
PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521660078/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom